Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
AMG-193 by Amgen for Metastatic Biliary Tract Cancer: Likelihood of Approval
AMG-193 is under clinical development by Amgen and currently in Phase II for Metastatic Biliary Tract Cancer. According to GlobalData,...
AMG-193 by Amgen for Esophageal Cancer: Likelihood of Approval
AMG-193 is under clinical development by Amgen and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II...
AMG-193 by Amgen for Gastric Cancer: Likelihood of Approval
AMG-193 is under clinical development by Amgen and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...
AMG-193 by Amgen for Glioma: Likelihood of Approval
AMG-193 is under clinical development by Amgen and currently in Phase II for Glioma. According to GlobalData, Phase II drugs...
AMG-193 by Amgen for Metastatic Biliary Tract Cancer: Likelihood of Approval
AMG-193 is under clinical development by Amgen and currently in Phase II for Metastatic Biliary Tract Cancer. According to GlobalData,...